Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Krishnan, P; Farhan, S; Schneider, P; Kamran, H; Iida, O; Brodmann, M; Micari, A; Sachar, R; Urasawa, K; Scheinert, D; Ando, K; Tarricone, A; Doros, G; Tepe, G; Yokoi, H; Laird, J; Zeller, T.
Determinants of Drug-Coated Balloon Failure in Patients Undergoing Femoropopliteal Arterial Intervention
J AM COLL CARDIOL. 2022; 80(13): 1241-1250.
Doi: 10.1016/j.jacc.2022.06.043
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Brodmann Marianne
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND Drug-coated balloons (DCB) are frequently used to treat femoropopliteal artery disease. However, patency loss occurs in $10% of patients within 12 months posttreatment with poor understanding of the underlying mechanisms.OBJECTIVES The authors sought to investigate the determinants of DCB failure in femoropopliteal disease.METHODS Data from randomized clinical trials (IN.PACT SFA, MDT-2113 SFA Japan) and 2 prespecified imaging cohorts of the IN.PACT Global Clinical Study were included. Influential procedural characteristics were evaluated by an inde-pendent angiographic core laboratory. The primary endpoint was DCB failure (patency loss during follow-up). Additional endpoints were binary restenosis and clinically driven target lesion revascularization. Multivariable analyses evaluated the clinical, anatomical, and procedural predictors of DCB failure.RESULTS Included were 557 participants with single lesions and 12-month core laboratory-adjudicated duplex ultra-sonography. Key clinical characteristics were as follows: mean age 68.8 years, 67.5% male, 87.6% with hypertension, 76.9% with hyperlipidemia, 40.5% with diabetes mellitus, 90.5% in Rutherford Classification Category (RCC) 2 to 3, and 9.5% in RCC 4 to 5. Average length and reference vessel diameter (RVD) were 16.37 cm and 4.66 mm, respectively; 49.7% of lesions were totally occluded. In multivariable analysis, only residual stenosis >30% was associated with patency loss, whereas residual stenosis >30% and smaller preprocedure RVD were associated with increased binary restenosis risk. RCC >3 and residual stenosis >30% were associated with increased 12-month clinically driven target lesion revascularization risk.CONCLUSIONS Patency loss after DCB treatment was influenced by procedural and clinical factors. Residual stenosis >30%, smaller preprocedure RVD, and higher RCC may be considered predictors of increased risk of DCB failure and its components in femoropopliteal artery disease. (Randomized Trial of IN.PACT Admiral (R) Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease [INPACT SFA I]; NCT01175850; IN.PACT Admiral Drug-Coated Balloon vs. Standard Balloon Angioplasty for the Treatment of Superficial Femoral Artery [SFA] and Proximal Popliteal Artery [PPA] [INPACT SFA II]; NCT01566461; MDT-2113 Drug-Eluting Balloon vs. Standard PTA for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery and/or Proximal Popliteal Artery [MDT-2113 SFA]; NCT01947478; IN.PACT Global Clinical Study; NCT01609296) (J Am Coll Cardiol 2022;80:1241-12 50) (c) 2022 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- Find related publications in this database (Keywords)
- drug-coated balloon
- drug-coated balloon failure
- femoropopliteal artery
- peripheral artery disease
- restenosis